Testing a tool to improve diversity in leukemia clinical trials
Feasibility Pilot of a Trial Enrollment Diversity Dashboard (TEDD)
This study is testing a new tool to help doctors include more diverse patients in leukemia clinical trials to make cancer research fairer for everyone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 12 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Dana-Farber Cancer Institute Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT06795139 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the Trial Enrollment Diversity Dashboard (TEDD), a data visualization tool designed to enhance participant diversity in acute leukemia clinical trials. By providing feedback to medical professionals on the diversity of their patient enrollments, TEDD seeks to address the underrepresentation of certain groups in cancer research. The study will involve approximately 12 medical professionals who treat leukemia patients, who will use the TEDD tool and provide feedback on its usability and effectiveness over a period of 14 months. The National Cancer Institute is funding this initiative to promote equitable representation in clinical trials.
Who should consider this trial
Good fit: Ideal candidates for this study include adult patients aged 18 and older diagnosed with leukemia, lymphoma, myeloma, or related diseases who are seen at the study sites.
Not a fit: Patients who do not have a diagnosis of leukemia or related diseases, or who are not seen at the study sites, will not benefit from this study.
Why it matters
Potential benefit: If successful, this tool could lead to more equitable representation in leukemia clinical trials, potentially improving treatment outcomes for diverse patient populations.
How similar studies have performed: While the approach of using a dashboard for diversity in clinical trials is innovative, similar initiatives aimed at improving diversity in clinical research have shown promise in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria Medical Professionals: * Physician, nurse practitioner, or physician assistant -≥10% clinical effort (or one ½ day of clinic per week for those working \<1 FTE) * Treats adult patients with leukemia or related diseases at the study sites * Ability to understand and willingness to provide informed consent * Age 18 or older Inclusion Criteria Participant Population: * Age ≥18 years old * Diagnosis of leukemia, lymphoma, myeloma, or related diseases * Seen by a physician for this diagnosis at one of the study sites Exclusion Criteria Medical Professionals: -Listed member of the research team Exclusion Criteria Participant Population: -Participants without the diagnoses of interest listed above, participants not seen at the study sites.
Where this trial is running
Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Andrew Hantel, MD — Dana-Farber Cancer Institute
- Study coordinator: Andrew Hantel, MD
- Email: Andrew_hantel@dfci.harvard.edu
- Phone: 617-582-9394
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.